Novo Nordisk Current Ratio 2010-2023 | NVO

Current and historical current ratio for Novo Nordisk (NVO) from 2010 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Novo Nordisk current ratio for the three months ending December 31, 2023 was 0.82.
Novo Nordisk Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2023-12-31 $20.28B $24.63B 0.82
2023-09-30 $20.76B $25.19B 0.82
2023-06-30 $20.10B $22.88B 0.88
2023-03-31 $16.42B $19.02B 0.86
2022-12-31 $15.32B $17.13B 0.90
2022-09-30 $16.17B $17.62B 0.92
2022-06-30 $14.73B $15.68B 0.94
2022-03-31 $13.05B $14.42B 0.91
2021-12-31 $13.62B $15.83B 0.86
2021-09-30 $14.47B $14.01B 1.03
2021-06-30 $12.51B $11.80B 1.06
2021-03-31 $9.95B $11.73B 0.85
2020-12-31 $10.08B $10.77B 0.94
2020-09-30 $11.57B $11.14B 1.04
2020-06-30 $10.87B $9.94B 1.09
2020-03-31 $9.33B $9.33B 1.00
2019-12-31 $9.36B $8.84B 1.06
2019-09-30 $9.45B $9.40B 1.01
2019-06-30 $8.84B $8.52B 1.04
2019-03-31 $8.03B $8.33B 0.96
2018-12-31 $9.03B $8.28B 1.09
2018-09-30 $8.45B $7.71B 1.10
2018-06-30 $9.21B $7.87B 1.17
2018-03-31 $8.24B $7.29B 1.13
2017-12-31 $9.13B $7.15B 1.28
2017-09-30 $9.02B $7.13B 1.27
2017-06-30 $8.72B $6.48B 1.35
2017-03-31 $7.98B $7.01B 1.14
2016-12-31 $8.88B $7.05B 1.26
2016-09-30 $7.74B $6.24B 1.24
2016-06-30 $7.99B $6.31B 1.27
2016-03-31 $6.86B $6.08B 1.13
2015-12-31 $8.21B $6.08B 1.35
2015-09-30 $7.68B $5.74B 1.34
2015-06-30 $7.02B $5.72B 1.23
2015-03-31 $6.59B $6.37B 1.04
2014-12-31 $8.25B $6.01B 1.37
2014-09-30 $7.33B $5.35B 1.37
2014-06-30 $6.29B $4.37B 1.44
2014-03-31 $6.34B $4.85B 1.31
2013-12-31 $7.49B $4.31B 1.74
2013-09-30 $7.27B $4.56B 1.59
2013-06-30 $6.40B $4.45B 1.44
2013-03-31 $6.34B $4.54B 1.40
2012-12-31 $6.94B $3.74B 1.86
2012-09-30 $6.87B $4.41B 1.56
2012-06-30 $6.21B $4.12B 1.51
2012-03-31 $6.41B $3.88B 1.65
2011-12-31 $7.40B $3.88B 1.91
2011-09-30 $7.37B $3.87B 1.91
2011-06-30 $7.31B $3.59B 2.04
2011-03-31 $6.51B $3.35B 1.94
2010-12-31 $6.65B $3.29B 2.02
2010-09-30 $5.87B $2.93B 2.00
2010-06-30 $5.78B $3.13B 1.85
2010-03-31 $5.84B $2.89B 2.02
2009-12-31 $6.12B $2.51B 2.44
2009-09-30 $5.95B $2.48B 2.40
2009-06-30 $5.44B $2.28B 2.38
2009-03-31 $5.02B $2.48B 2.03
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $558.743B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $714.182B 118.93
Johnson & Johnson (JNJ) United States $355.491B 14.14
Merck (MRK) United States $318.503B 83.83
AbbVie (ABBV) United States $287.341B 14.61
AstraZeneca (AZN) United Kingdom $213.711B 18.94
Novartis AG (NVS) Switzerland $198.225B 13.73
Pfizer (PFE) United States $146.433B 14.13
Sanofi (SNY) $116.185B 10.46
Innoviva (INVA) United States $0.925B 6.53